看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 4.3x - 4.7x | 4.5x |
| Selected Fwd Ps Multiple | 1.9x - 2.1x | 2.0x |
| Fair Value | $2.54 - $2.81 | $2.67 |
| Upside | 17.0% - 29.3% | 23.2% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| AbbVie Inc. | - | NYSE:ABBV |
| Dyadic International, Inc. | - | NasdaqCM:DYAI |
| Onconetix, Inc. | - | NasdaqCM:ONCO |
| Cardiff Oncology, Inc. | - | NasdaqCM:CRDF |
| Geron Corporation | - | NasdaqGS:GERN |
| Elutia Inc. | - | NasdaqCM:ELUT |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| ABBV | DYAI | ONCO | CRDF | GERN | ELUT | |||
| NYSE:ABBV | NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqCM:CRDF | NasdaqGS:GERN | NasdaqCM:ELUT | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 11.1% | 15.8% | NM- | 22.8% | 178.4% | -10.7% | ||
| 3Y CAGR | 0.1% | 13.3% | NM- | 23.9% | 280.9% | -19.9% | ||
| Latest Twelve Months | 3.7% | 20.6% | NM | 40.0% | 32386.9% | -1.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 15.2% | -404.2% | -19098.5% | -7594.3% | -23982.0% | -113.4% | ||
| Prior Fiscal Year | 8.9% | -234.4% | NA | -8496.9% | -77690.7% | -166.7% | ||
| Latest Fiscal Year | 7.5% | -166.2% | -63986.5% | -6655.2% | -226.7% | -222.1% | ||
| Latest Twelve Months | 7.5% | -166.2% | -2758.7% | -6655.2% | -226.7% | -222.1% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 13.9x | NA | -1.3x | -1.5x | -2.9x | -4.8x | ||
| Price / LTM Sales | 5.5x | 10.7x | 0.3x | 240.6x | 11.4x | 3.6x | ||
| LTM P/E Ratio | 73.1x | -6.4x | 0.0x | -3.6x | -5.0x | -1.6x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.3x | 10.7x | 240.6x | |||||
| Historical LTM P/S Ratio | 1.7x | 2.4x | 3.6x | |||||
| Selected Price / Sales Multiple | 4.3x | 4.5x | 4.7x | |||||
| (x) LTM Sales | 24 | 24 | 24 | |||||
| (=) Equity Value | 104 | 109 | 115 | |||||
| (/) Shares Outstanding | 40.7 | 40.7 | 40.7 | |||||
| Implied Value Range | 2.55 | 2.69 | 2.82 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 2.55 | 2.69 | 2.82 | 2.17 | ||||
| Upside / (Downside) | 17.6% | 23.8% | 29.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ABBV | DYAI | ONCO | CRDF | GERN | ELUT | |
| Value of Common Equity | 309,660 | 37 | 1 | 164 | 879 | 88 | |
| (/) Shares Outstanding | 1,769.0 | 30.1 | 8.3 | 66.5 | 636.9 | 40.7 | |
| Implied Stock Price | 175.05 | 1.24 | 0.06 | 2.47 | 1.38 | 2.17 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 175.05 | 1.24 | 0.06 | 2.47 | 1.38 | 2.17 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |